TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39109241
Drug: Pain Relief
Normalized name: Pain Relief
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain Relief Patch (PRP) delivering blue light for 30 minutes during five treatment sessions
Study: 39110045
Drug: Crano-cure (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crano-cure (500 mg capsules, two times a day for 28 days)
Study: 39110045
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg tablets, two times a day for 28 days)
Study: 39110427
Drug: Low-dose DOAC
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose DOAC (apixaban, 2.5 mg every 12 hours)
Study: 39110427
Drug: DAPT (aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAPT (aspirin 100 mg per day plus clopidogrel 75 mg per day)
Study: 39110497
Drug: VR-based training
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VR-based training with machine guidance (MG)
Study: 39110497
Drug: Correlation between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation between training duration and VR exam scores for MG group
Study: 39110531
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg once daily (QD)
Study: 39110531
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg 3 times/week (TIW)
Study: 39110531
Drug: Exemestane 25
Normalized name: exemestane 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exemestane 25 mg per week (QW)
Study: 39110721
Drug: Fixation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixation of B2 PFFs around cemented polished taper-slip stems with an intact bone-cement interface
Study: 39111387
Drug: Eat Well
Normalized name: MENTHOL 160 mg in 1 mL TOPICAL SPRAY [Cool n Heat Well at Walgreens]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eat Well (intervention arm) - debit card with $80 added monthly for 12 months for fresh, frozen, or canned fruits and vegetables.
Study: 39112102
Drug: Sodium zirconium
Normalized name: Sodium zirconium silicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sodium zirconium cyclosilicate (SZC) 10 g TID during the OLP
Study: 39112464
Drug: Sacituzumab Govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sacituzumab Govitecan (SG) at 10 mg/kg, administered as a single intravenous dose one day before resection and continued on days 1 and 8 of 21-day cycles following recovery.
Study: 39112489
Drug: 4CMenB (Bexsero,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB (Bexsero, GSK) vaccine, two doses
Study: 39112489
Drug: 4CMenB (Bexsero,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB (Bexsero, GSK) vaccine
Study: 39112628
Drug: Alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 70 mg weekly for 12 months (N=10)
Study: 39113067
Drug: Rosuvastatin (when
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (when LDL-C < 70 mg/dL)
Study: 39113067
Drug: Atorvastatin (when
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (when LDL-C < 70 mg/dL)
Study: 39113190
Drug: Neoadjuvant AC-T
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant AC-T chemotherapy with metformin
Study: 39113266
Drug: Mobile application
Normalized name: Mahana IBS CBT Mobile Application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile application for urinary incontinence treatment
Study: 39114274
Drug: Sutimlimab (C1s
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sutimlimab (C1s inhibitor), biweekly doses for up to 1 year after Part A
Study: 39114536
Drug: THC/CBD combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC/CBD combination
Study: 39114536
Drug: THC alone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC alone, CBD alone, THC/CBD combination, Placebo
Study: 39114870
Drug: Zanidatamab treatment
Normalized name: Zanidatamab
DrugBank: Zanidatamab (DB15471)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanidatamab treatment (administered once every 2 weeks)
Study: 39114870
Drug: Zanidatamab treatment
Normalized name: Zanidatamab
DrugBank: Zanidatamab (DB15471)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanidatamab treatment
Study: 39114916
Drug: Erythritol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythritol (30 g)
Study: 39115062
Drug: Nipocalimab (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nipocalimab (30 or 45 mg per kilogram of body weight per week) administered from 14 to 35 weeks' gestation
Study: 39115062
Drug: Nipocalimab treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nipocalimab treatment
Study: 39115419
Drug: mRNA-4157 (1-mg)
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-4157 (1-mg)
Study: 39115419
Drug: mRNA-4157 (1-mg)
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-4157 (1-mg) + Pembrolizumab (200-mg)
Study: 39115608
Drug: Community-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based intervention (information campaigns on AF diagnosis and therapies)
Study: 39116153
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine therapy
Study: 39116333
Drug: CETA-PWH (moderate
Approvals — FDA: no, EMA: no, PMDA: no
Description: CETA-PWH (moderate dose)
Study: 39116435
Drug: Active control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active control program (computer games designed for entertainment, e.g., Solitaire)
Study: 39116448
Drug: ML models
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ML models (eXtreme Gradient Boosting, Feedforward Neural Network, Logistic Regression, Support Vector Machine)
Study: 39116486
Drug: Quadrivalent inactivated
Normalized name: Fluarix Quadrivalent 2018-2019
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent inactivated influenza vaccine (IIV4) - three manufacturing lots, single dose.
Study: 39116902
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan 5·4 mg/kg
Study: 39116902
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan 6·4 mg/kg
Study: 39116904
Drug: Butantan-DV (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butantan-DV (0.5 mL single dose)
Study: 39117488
Drug: PEG-EPO (0.2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-EPO (0.2, 0.4, 0.8, 1.6, 2.4, 3.6, or 4.8 µg/kg)
Study: 39117670
Drug: Nivolumab 360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 360 mg iv on day 1, carboplatin AUC 5 iv on day 1, etoposide 100 mg/m2 iv on days 1-3
Study: 39117964
Drug: Glibenclamide 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide 3.75 mg/day for 7 days
Study: 39118415
Drug: Treatment interventions
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment interventions for neonatal complications
Study: 39119004
Drug: Lugol's solution
Normalized name: Lugol's Solution
DrugBank: Potassium triiodide (DB14492)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lugol's solution 5%, three oral drops thrice daily for 10 days
Study: 39120779
Drug: Project Share
Normalized name: shark preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Project Share (Supportive Therapy)
Study: 39120902
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for insomnia integrated in best-evidence pain management (CBTi-BEPM)
Study: 39121478
Drug: Automated SMS
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated SMS text message intervention, 2 daily messages for 4 weeks
Study: 39121698
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of Ad26.COV2·S
Study: 39122384
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lactoferrin and lysozyme
Study: 39122389
Drug: Dose-volume constraints
Normalized name: Constrained Metal (Curcuma Longa)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-volume constraints derived from statistical model in PredicT A
Study: 39122389
Drug: Dose-volume constraints
Normalized name: Constrained Metal (Curcuma Longa)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-volume constraints tested in PredicT B
Study: 39122788
Drug: m-DOT (mobile
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-DOT (mobile Directly Observed Therapy) with hydroxyurea (15 mg/kg daily for three months)
Study: 39122788
Drug: Standard monitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard monitoring with hydroxyurea (15 mg/kg daily for three months)
Study: 39125394
Drug: Teduglutide (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teduglutide (0.05 mg/kg/day)
Study: 39125394
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition and/or intravenous fluids (mean volume)
Study: 39125451
Drug: Glycocalyx dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glycocalyx dietary supplement (GDS), n = 25
Study: 39126603
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) formulation of donepezil at doses of 70, 140, and 280 mg
Study: 39126603
Drug: Oral formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral formulation of donepezil at 10 mg
Study: 39126720
Drug: Clazosentan (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazosentan (15 mg/hour intravenous)
Study: 39126937
Drug: Melatonin 5
Normalized name: melatonin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 5 mg daily
Study: 39126937
Drug: Melatonin 3
Normalized name: melatonin 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 3 mg daily
Study: 39127745
Drug: Atezolizumab in
Normalized name: atezolizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab in combination with chemotherapy with or without bevacizumab
Study: 39128498
Drug: Methionine test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine test intake (range: 0-40 mg⋅kg) during early gestation (11-20 weeks)
Study: 39128498
Drug: Methionine test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine test intake (range: 0-40 mg⋅kg) during late gestation (31-40 weeks)
Study: 39538331
Drug: Neoantigen DNA
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoantigen DNA vaccine
Study: 39129005
Drug: Oral Myofunctional
Normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Myofunctional Therapy (OMT)
Study: 39129619
Drug: Lugol solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lugol solution (7 days treatment)
Study: 39129619
Drug: No Lugol
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Lugol treatment (control group)
Study: 39130023
Drug: High-sensitivity cardiac
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sensitivity cardiac troponin T (hs-cTnT) detectable in 80.7% of patients; median hs-cTnT 10 ng/L (IQR: 6-18 ng/L)
Study: 39130025
Drug: Antithrombotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic therapy for AF in cancer patients
Study: 39130140
Drug: Intravascular lithotripsy
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravascular lithotripsy (IVL) as an adjunct to coronary stenting
Study: 39131140
Drug: Erlotinib 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 75 mg/day
Study: 39131140
Drug: Erlotinib 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 50 mg/day
Study: 39131140
Drug: Erlotinib 25
Normalized name: erlotinib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 25 mg/day
Study: 39131144
Drug: Oral 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 8 mg insulin
Study: 39131668
Drug: Colesevelam administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam administered with mixed meal tests
Study: 39132049
Drug: Canocapavir 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canocapavir 25 mg
Study: 39132049
Drug: Canocapavir 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canocapavir 75 mg
Study: 39132049
Drug: Canocapavir 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canocapavir 150 mg
Study: 39132049
Drug: Canocapavir 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canocapavir 300 mg
Study: 39132049
Drug: Canocapavir 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canocapavir 450 mg
Study: 39132049
Drug: Canocapavir 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canocapavir 75 mg (multiple ascending dose)
Study: 39132049
Drug: Canocapavir 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canocapavir 150 mg (multiple ascending dose)
Study: 39132049
Drug: Canocapavir 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canocapavir 300 mg (multiple ascending dose)
Study: 39132075
Drug: Low-residue diet
Normalized name: hydroxypropyl betadex (0.6 hydroxypropyl residues per glucose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-residue diet (LRD) (<10 g fiber per day)
Study: 39132187
Drug: Prescription Digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription Digital Therapeutic (PDT) containing cognitive behavioral therapy for 90 days
Study: 39133474
Drug: Oral apixaban,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral apixaban, 5 mg (or 2.5 mg if criteria met), twice daily
Study: 39133474
Drug: Oral aspirin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral aspirin, 81 mg, once daily
Study: 39133474
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of apixaban vs aspirin among those with cancer
Study: 39133680
Drug: Standardized pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized pain medication tapering program
Study: 39133680
Drug: Personalized pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized pain medication tapering program
Study: 39133680
Drug: No tapering
Approvals — FDA: no, EMA: no, PMDA: no
Description: No tapering program
Study: 39134085
Drug: Intraurethral LBP-EC01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraurethral LBP-EC01 (2 days) and intravenous LBP-EC01 (1×10) for 3 days
Study: 39134346
Drug: Neoadjuvant anti-PD-1
Normalized name: Dianeal PD-2/1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant anti-PD-1 therapy
Study: 39134346
Drug: Supplement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement of anti-TIM-3
Study: 39134346
Drug: Tumor and
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor and paired lung samples from treatment-naïve patients
Study: 39134434
Drug: Low-dose sesame
Normalized name: Sesame Oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose sesame oral immunotherapy (OIT) with a 300 mg maintenance dose of sesame protein administered once daily for up to 18 months
Study: 39134434
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment including an elimination diet and observation for 1 year
Study: 39134434
Drug: Low-dose sesame
Normalized name: Sesame Oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose sesame oral immunotherapy (OIT)
Study: 39134434
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment including an elimination diet
Study: 39134652
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg every 3 weeks for ≤35 cycles with ongoing enzalutamide until progression, unacceptable toxicity, or withdrawal (C4)
Study: 39134652
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg every 3 weeks for ≤35 cycles with ongoing enzalutamide until progression, unacceptable toxicity, or withdrawal (C5)
Study: 39134652
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg every 3 weeks for ≤35 cycles with ongoing enzalutamide until progression, unacceptable toxicity, or withdrawal (C4 and C5 combined)
Study: 39134667
Drug: Breast milk
Normalized name: BREAST MILK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast milk (2 ml orally)
Study: 39135126
Drug: Minodronate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minodronate (1 mg/day)
Study: 39135209
Drug: Mesenchymal stromal/stem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal stromal/stem cells (MSCs) therapy
Study: 39135452
Drug: Tofacitinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib treatment from baseline to week 18
Study: 39135540
Drug: Efzimfotase alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efzimfotase alfa (15 mg, 45 mg, or 90 mg) administered as one intravenous (i.v.) dose followed by 3 weekly subcutaneous (s.c.) doses.
Study: 39136011
Drug: Zerafil (omalizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zerafil (omalizumab biosimilar) administered at a dose ranging from 150 to 375 mg based on pre-treatment serum total IgE level and body weight every two or four weeks for 28 weeks.
Study: 39136011
Drug: Omalizumab (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab (reference product) administered at a standard dose.
Study: 39136260
Drug: Daily headache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily headache diary
Study: 39136560
Drug: Selective prostatic
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective prostatic arterial administration of gallium 68 PSMA PET/CT radioligand
Study: 39136560
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of gallium 68 PSMA PET/CT radioligand
Study: 39136801
Drug: TransCon PTH
Normalized name: TransCon PTH
DrugBank: Palopegteriparatide (DB18676)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TransCon PTH treatment
Study: 39137167
Drug: Oral resveratrol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral resveratrol (40 mg twice a day for 1 week, then 20 mg twice a day for 6 months)
Study: 39137167
Drug: Matched oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched oral placebo
Study: 39137185
Drug: Self-sampling kits
Normalized name: orchard grass pollen extract
DrugBank: Dactylis glomerata pollen (DB10379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-sampling kits offered to women overdue for cervical cancer screening (CC) during breast cancer screening.
Study: 39137185
Drug: Self-sampling offered
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-sampling offered to women overdue for CC screening.
Study: 39137617
Drug: In-beam Positron
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-beam Positron Emission Tomography (PET) monitoring during carbon therapy
Study: 39137624
Drug: Ketone ester
Normalized name: Ketonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketone ester (25 g bis-octanoyl (R)-1,3-butanediol)
Study: 39138024
Drug: Fetal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fetal therapy (including thoracoamniotic shunts, antenatal steroids, and combination therapies)
Study: 39138436
Drug: Erdafitinib 8
Normalized name: erdafitinib
DrugBank: Erdafitinib (DB12147)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erdafitinib 8 mg once daily (with option for up-titration to 9 mg) or 10 mg (7 days on/7 days off for 4 NSCLC patients)
Study: 39138719
Drug: Active PPF-block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active PPF-block (5-mL injectates of 20 mg of ropivacaine plus 4 mg of dexamethasone)
Study: 39138719
Drug: Placebo PPF-injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo PPF-injection (saline solution)
Study: 39138719
Drug: Placebo PPF-injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo PPF-injection
Study: 39138826
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of miR-151a-3p or miR-21-5p with leptin
Study: 39138826
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of miR-151a-3p with glucose
Study: 39138826
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of miR-126-5p with leptin
Study: 39139218
Drug: Vedolizumab (week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vedolizumab (week 6 serum concentration >41.65 µg/ml)
Study: 39139269
Drug: Early vitrectomy
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early vitrectomy surgery in addition to antibiotic administration
Study: 39139269
Drug: Intravitreal antibiotic
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal antibiotic administration alone (standard of care)
Study: 39139270
Drug: tezacaftor-ivacaftor (TEZ/IVA),
Approvals — FDA: no, EMA: no, PMDA: no
Description: tezacaftor-ivacaftor (TEZ/IVA), 28 days treatment duration
Study: 39139270
Drug: placebo, 28
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, 28 days treatment duration
Study: 39140289
Drug: Safusidenib treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safusidenib treatment following biopsy and prior to surgical resection
Study: 39140727
Drug: Caffeine loading
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine loading dose
Study: 39141364
Drug: Baricitinib (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib (both doses)